Charlie Evans, 13, who suffers from severe food allergies and eosinophilic esophagitis (EoE), takes part in an NIH-funded study at Cincinnati Children's hospital. The NIH dismissed the hospital's ...

Following an FDA rejection last year, the drugmakers plan to resubmit their application for an expanded approval of Dupixent in chronic spontaneous urticaria. But Sanofi and Regeneron have encountered ...

Dupixent continues to be Regeneron’s standout performer, with global net sales reaching $4.9 billion in Q3 2025, representing impressive 26% year-over-year growth. The drug now serves more than 1.3 ...

Regeneron Pharmaceuticals (NASDAQ:REGN) presented its third-quarter 2025 corporate update on October 28, highlighting strong financial performance and continued growth across its key product ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending ...

In one five-word sentence, Pen Argyl Area High School senior center Xavier Ragusa accurately summed up the Green Knights’ 32-21 victory over Bangor in the 106th meeting between the Slate Belt rivals ...

Roberts went to the 'pen for the right-handed-hitting Ernie Clement. Sheehan, who is typically a starter, inherited the bases loaded with nobody out. It was Sheehan's first time entering in a dirty ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. REGN reports third-quarter 2025 results on Oct. 28, 2025. The Zacks ...